Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2007-03-13
2007-03-13
Tate, Christopher R. (Department: 1655)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
Reexamination Certificate
active
10288253
ABSTRACT:
This invention involves the new use of a diagnostic test to determine the risk of atherosclerotic diseases such as myocardial infarction and stroke, particularly among individuals with no signs or symptoms of current disease and among nonsmokers. Further, this invention involves the new use of a diagnostic test to assist physicians in determining which individuals at risk will preferentially benefit from certain treatments designed either to prevent first or recurrent myocardial infarctions and strokes, or to treat acute and chronic cardiovascular disorders. Methods for treatment also are described.
REFERENCES:
patent: 6117642 (2000-09-01), Crow et al.
patent: 6369065 (2002-04-01), Chatelain et al.
patent: WO 98/20155 (1998-05-01), None
patent: WO 98/43630 (1998-10-01), None
patent: WO 01/15744 (2001-03-01), None
Aukrust et al, “Circulation”, V. 100, pp. 614-620, 1999.
Koenig et al, “Circulation”, V.99, pp. 237-242, 1999.
Koenig, Wolfgang, Ital. Heary J, V. 2(3), pp. 157-163 (2001).
Aukrust, P{dot over (a)}l et al., “Enhanced Levels of Soluble and Membrane-Bound CD40 Ligand in Patients With Unstable Angina,”Circulation, 1999, vol. 100, pp. 614-620.
Brignole, F. et al., “Flow Cytometric Analysis of Inflammatory Markers in KCS: 6-Month Treatment With Topical Cyclosporin A,”Invest Opthalmol Vis Sci., Jan. 2001; vol. 42, No. 1, pp. 90-95.
di Marzio, P. et al., “Soluble CD40 Ligand Induces β-chemokines Production by Macrophage and Resistance to HIV-1 Entry,”Cytokine, Oct. 2000, vol. 12, No. 10, pp. 1489-1495.
Foy, Theresa M. et al., “Immune Regulation By CD40 and its Ligand GP39,”Annu. Rev. Immunol.1996, vol. 14, pp. 591-617.
Henn, V. et al., “CD40 Ligand on Activated Platelets Triggers an Inflammatory Reaction of Endothelial Cells,”Nature, Feb. 5, 1998, vol. 391, No. 6667, pp. 591-594.
International Search Report for PCT/US02/35505, Date of completion of international search: Aug. 18, 2003.
Kornbluth, Richard et al., “CD40 Ligand (CD154) Stimulation of Macrophages to Produce HIV-1-Suppressive β-chemokines,” Proc. Natl. Acad. Sci, Apr. 1998, vol. 95, pp. 5205-5210.
Mach, François et al., “Activation of Monocyte/Macrophage Functions Related to Acute Atheroma Complication by Ligation of CD40,”Circulation, 1997, vol. 96, pp. 396-399.
Mach, François et al., “T Lymphocytes Induce Endothelial Cell Matrix Metalloproteinase Expression by a CD40L-Dependent Mechanism,”American Journal of Pathology, Jan. 1999, vol. 154, No. 1, pp. 229-238.
Phipps, Richard P., “Atherosclerosis: The Emerging Role of Inflammation and the CD40—CD40 Ligand System,”PNAS, Jun. 20, 2000, vol. 97, No. 13, pp. 6930-6932.
Schönbeck, U. et al., “CD40 Ligation Induces Tissue Factor Expression in Human Vascular Smooth Muscle Cells,”American Journal of Pathology, Jan. 2000, vol. 156, No. 1, pp. 7-14.
Schönbeck, U. et al., “Inhibition of CD40 Signaling Limits Evolution of Established Atherosclerosis in Mice,”PNAS, Jun. 20, 2000, vol. 97, No. 13, pp. 7458-7463.
Szabolcs, M.J. et al., “Analysis of CD154 and CD40 Expression in Native Coronary Atherosclerosis and Transplant Associated Coronary Artery Disease,”Virchows Arch., Aug. 2000, vol. 437, No. 2, pp. 149-159.
Bogaert, M., et al., “Gecommentrarieerd geneesmiddelenrepertorium 2001”, Belgisch Centrum Vor Farmacotherapeutische Informatie, XP 002361328.
Elwood, P.C., “Aspirin in the Prevention of Myocardial Infarction Current Status,”Drugs,vol. 28, pp. 1-5 (1984).
Schonebeck, U., et al., “Soluble CD40L and Cardiovascular Risk in Women,”Circulation, vol. 104, pp. 2266-2268 (2001).
Varo, Nerea, et al., “Elevated sCD40L plasma concentrations in women correlates to enhanced relative risk of future cardiovascular events,”Circulation, vol. 104, No. 17 Supplement, pp. II. 779 (2001).
Libby Peter
Ridker Paul
Schönbeck Uwe
Tate Christopher R.
The Brigham and Women's Hospital, Inc.
Wolf Greenfield & Sacks P.C.
Wood Amanda P.
LandOfFree
Soluble CD40L(CD154) as a prognostic marker of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Soluble CD40L(CD154) as a prognostic marker of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Soluble CD40L(CD154) as a prognostic marker of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3737107